Hutchison China MediTech (AIM, NASDAQ:HCM) has initiated a U.S. Phase 1 bridging clinical trial of fruquintinib, a highly selective and potent oral inhibitor of vascular endothelial growth factor receptors 1, 2 and 3, that has met its primary endpoint in several Phase 2 and 3 clinical trials in China for the treatment of colorectal, lung and gastric cancers.Read More
H.C. Wainwright raised its price target for Calithera Biosciences (NASDAQ:CALA) to $14 from $10, citing a recent partnership with Incyte and dilution from recent rounds of fund raising. The stock closed at $10.75 on March 28.Read More
GeneNews (TSX:GEN) has signed an agreement with a large, multi-specialty physician group in the American Midwest for use of its cancer diagnostic tests.Read More
H.C. Wainwright initiated coverage of Bellerophon Therapeutics (NASDAQ:BLPH) with a “buy” rating and price target of $5. The stock closed at 67 cents on Jan. 20.Read More
Roth Capital Partners has initiated coverage on Biocept (NASDAQ:BIOC) with a “buy” rating and target price of $1.20. The stock closed at 63 cents on Monday.
“Through its proprietary technology platform capable of assaying both circulating tumor cells (CTCs) and circulating tumor DNA (ctDNA), strong IP portfolio, notable collaborations with leading cancer institutions, and building commercial momentum, we believe Biocept is uniquely positioned as a leader in the emerging field of liquid biopsy and personalized medicine,” writes analyst Chris Lewis.Read More